Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Therapeutic Research Protocol Dose: 0.5 0.75 mg (variant 5 mg pen = 2030 clicks / variant 10 mg pen = 1015 clicks) Duration: 4 6 weeks Frequency: Daily Cycle Interval: 4 weeks off before next cycle Goal / Description: Used in muscle or tendon repair studies
Do you add any other ingredients
Ghrelin acts on reward-related pathways by stimulating dopamine neurons in the ventral tegmental area and promoting dopamine turnover in the nucleus accumbens, a region of the ventral striatum (Xerfan et al., 2026), implicating that the anti-inflammatory properties of GLP-1 RAs could also be beneficial
8-12 hours IM) Preferred by 64% of patients who've tried both Intramuscular (into deltoid or vastus lateralis, using a 22-25 gauge, 1-inch needle): 41% report injection-site soreness Faster absorption More difficult self-administration for some sites (deltoid requires non-dominant arm injection) Preferred by 36% of patients who've tried both The efficacy difference is minimal
Furthermore, a prespecified subgroup analysis of HF individuals from the SELECT trial evaluating the effects of semaglutide on cardiovascular outcomes in people with overweight or obesity, which included 2,273 HFpEF and 1,347 HFrEF patients, showed that the therapy was associated with a reduction in the HF composite outcome (cardiovascular death or HF hospitalisation/emergency visit) across LVEF, suggesting that GLP-1 RAs may improve outcomes at least in obese HF patients regardless of diabetes status
